Companies / Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

Nasdaq: AVXLCIK 1314052NEW YORK, NY

Financials

Revenue
Net income$-46.38M
Total debt$345
Cash$131.75M
Diluted EPS$-0.54
Shares outstanding92.7M

Ownership

92.7M shares outstanding · as of Feb 9, 2026
41.7%Institutions
Ownership
Institutions41.75%38,687,655
Public float58.25%53,984,103

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Boenisch SandraPFO & Treasurer
Kellmeyer TerrieCEOInterim CEO
Missling Christopher UCEOPresident and CEO · Director
Paeger AxelDirector

Institutional holders 189

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q2 2026
as of
State Street Corporation
13F manager
TrimCommon stock$-6.37M-2.5M
-56.14%
1,922,770
2.07% of shares
medium
Q1 2026
as of
Two Sigma Investments, LP
13F manager
AddCommon stock$4.89M+1.6M
+96.40%
3,247,888
3.50% of shares
low
Q1 2026
as of
AQR Capital Management, LLC
13F manager
AddCommon stock$1.86M+607K
+405.15%
756,792
0.82% of shares
low
Q1 2023
as of
Barclays PLC
13F manager
AddCommon stock$1.54M+180K
+1796.13%
189,613
0.20% of shares
low
Q3 2025
as of
Nwam LLC
13F manager
TrimCommon stock$-1.41M-150K
-14.66%
874,283
0.94% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
AddCommon stock$1.37M+529K
+7.04%
8,055,628
8.69% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
AddCommon stock$1.26M+353K
+206.75%
524,189
0.57% of shares
low
Q2 2025
as of
Barclays PLC
13F manager
AddCommon stock$1.25M+136K
+91.19%
284,259
0.31% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A0

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AVXL032797300